Stock Market Reviews

Read and share opinions on TIL (Instil Bio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Nov 13, 2025
• Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio
  Oct 21, 2025
• Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
  Sep 10, 2025
• Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
  Aug 16, 2025
• Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Aug 13, 2025
• ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
  Jul 31, 2025
• Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
  Jul 2, 2025
• Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
  Jun 20, 2025
• Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
  Jun 16, 2025
• Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
  Jun 11, 2025
• Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
  Jun 4, 2025
• Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
  Jun 2, 2025
• Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
  May 30, 2025
• Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
  May 29, 2025
• Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
  May 29, 2025
• Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
  May 23, 2025
• Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
  May 22, 2025
• Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
  May 13, 2025